Reasoning
This is a scale-conversion story, not a science-project story. The company already has live robots, large platform embeds, and enough liquidity to pursue density. If it proves that active robots, hospital workflows, and software or data revenue can compound together, investors can justify a strong premium to commodity robotics. The upside is meaningful, but partner concentration and regulation likely keep it below the most extreme outcomes.